ReviewBritish journal of pharmacology2016
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Review in British journal of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 63 citations in OpenAlex.
- Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.BMC cancer · 2026Article
- TAPINTO: A Novel Algorithm for Tumor-Associated Antigen Prediction Based on Information about Target Overexpression.Computational and structural biotechnology journal · 2026Article
- The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.British journal of pharmacology · 2025Review
- Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025Review
- A New Protein-Ligand Trapping System to Rapidly Screen and Discover Small-Molecule Inhibitors of PD-L1 from Natural Products.Molecules (Basel, Switzerland) · 2025Article
- Design, Production, and Optimization of Antigen-Specific Recombinant Antitumor Dimeric IgA Antibody.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators.Cancers · 2023Review
- Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging.Biomedicines · 2023Review
- Receptor tyrosine kinase inhibitors in cancer.Cellular and molecular life sciences : CMLS · 2023Review
- Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?Current oncology (Toronto, Ont.) · 2023Article
- Beta-Blockers and Cancer: Where Are We?Pharmaceuticals (Basel, Switzerland) · 2020Review
- Review
- Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line.Scientific reports · 2019Article
- Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies.Journal of pharmaceutical sciences · 2018Article
- Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma.Scientific reports · 2018Article
- An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.EMBO molecular medicine · 2018Article
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.Nucleic acids research · 2018Article
- Current progress in innovative engineered antibodies.Protein & cell · 2018Review
- An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E.PloS one · 2018Article
- Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Antibody-based therapy of cancer employs monoclonal antibodies (mAbs) specific to soluble ligands, membrane antigens of T-lymphocytes or proteins located at the surface of cancer cells. The latter mAbs are often combined with cytotoxic regimens, because they block survival of residual fractions of tumours that evade therapy-induced cell death. Antibodies, along with kinase inhibitors, have become in the last decade the mainstay of oncological pharmacology. However, partial and transient responses, as well as emergence of tumour resistance, currently limit clinical application of mAbs. To overcome these hurdles, oligoclonal antibody mixtures are being tested in animal models and in clinical trials. The first homo-combination of two mAbs, each engaging a distinct site of HER2, an oncogenic receptor tyrosine kinase (RTK), has been approved for treatment of breast cancer. Likewise, a hetero-combination of antibodies to two distinct T-cell antigens, PD1 and CTLA4, has been approved for treatment of melanoma. In a similar vein, additive or synergistic anti-tumour effects observed in animal models have prompted clinical testing of hetero-combinations of antibodies simultaneously engaging distinct RTKs. We discuss the promise of antibody cocktails reminiscent of currently used mixtures of chemotherapeutics and highlight mechanisms potentially underlying their enhanced clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.